Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal dominant severe congenital neutropenia in which the cause of the disease is a mutation in the GFI1 gene.
Features include: Increased total monocyte count, Decreased total B cell count, and Decreased total neutrophil count.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 1 | Decreased total neutrophil count |
GFI1 encodes growth factor independent 1 transcriptional repressor (422 aa). Transcription repressor essential for hematopoiesis. Functions in a cell-context and development-specific manner. Binds to 5'-TAAATCAC[AT]GCA-3' in the promoter region of a large number of genes. Highest expression in Cells EBV-transformed lymphocytes (12.6 TPM) and Spleen (9.7 TPM).
Neutropenia, severe congenital, 2, autosomal dominant is associated with mutations in the GFI1 gene on chromosome 1.
The GFI1 protein participates in GFI1 gene expression is enhanced by CEBPA, RUNX2 gene expression from distal (P1) promoter is inhibited by NKX3-2, MSX2 and RUNX2-P1, and stimulated by DLX5,(DLX6), and Transcriptional regulation of granulopoiesis pathways.
GFI1 is classified as a druggable target with score 0.0.
Genetic testing for GFI1 is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for neutropenia, severe congenital, 2, autosomal dominant.
6 publications have been identified in PubMed for neutropenia, severe congenital, 2, autosomal dominant. Research spans Review / Meta-Analysis (50%), Basic Science / Preclinical (33%), and Case Report / Case Series (17%).
Sun Y (2026). [PMID: 41560087](https://pubmed.ncbi.nlm.nih.gov/41560087/). *Medicine (Baltimore)*. [Review / Meta-Analysis]
van Bergen T (2026). [PMID: 41056520](https://pubmed.ncbi.nlm.nih.gov/41056520/). *Blood Adv*. [Basic Science / Preclinical]
Kim JM (2026). [PMID: 42040242](https://pubmed.ncbi.nlm.nih.gov/42040242/). *Neurol Genet*. [Case Report / Case Series]
Min KI (2025). [PMID: 40418265](https://pubmed.ncbi.nlm.nih.gov/40418265/). *Blood Res*. [Review / Meta-Analysis]
Marti S (2025). [PMID: 40510848](https://pubmed.ncbi.nlm.nih.gov/40510848/). *Hemasphere*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:08 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center